PharmiWeb.com - Global Pharma News & Resources
15-Feb-2019

Global Erythropoietin (EPO) Drugs Market Key Players, Competitive Strategies, Regional Analysis Forecast 2028

Erythropoietin is a hormone largely produce by the capillary network of renal cortex of the Kidney and also in minor quantity produce by liver and brain which stimulate the formation of red blood cells (RBCs). Erythropoietin (EPO), also known as hematopoietin or hemopoietin. Chemically, erythropoietin a protein with an attached sugar. It is glycoproteins that help to stimulate the growth of specific types of blood cells in the bone marrow. The kidney cells produce and release erythropoietin when the level of oxygen is very low in the blood. Erythropoietin drugs are used to treat anaemia caused due to chronic kidney diseases(CKD), cancer and human immunodeficiency virus (HIV). Normal levels of erythropoietin range from 4 up to 24 mU/ml (milliunits per millilitre).

Increasing prevalence of patients with chronic kidney dysfunction disease(CDK), cancer, acquired immune deficiency syndrome (AIDS) and bone marrow dysfunction are expected to drive the growth of erythropoietin drug market. Other factors include upsurge in drug patent expiration which in turn are shifting vendors to emphasize on using biosimilar medicines having same therapeutic effect with lower cost, growing geriatrics patient’s population, raising deficiency of iron, vitamin B12 and folic acid due to sedentary lifestyle and  increase in blood transfusion during surgeries and treatment (solid tumours, malignant lymphoma or multiple myeloma, cardiovascular status) are anticipated to drive the growth of EPO drug market worldwide.

Unaffordability of therapeutics medication process and longer duration of treatments are some of the factors that can inhibit the growth of the global EPO market to a certain extent.

Currently, EPO pills is in a nascent stage of development. Epogen or Procrit is most common medication used to aid patients with kidney disease who require dialysis to both treat and prevent anaemia. All the medicated drugs are injected intravenously (into a vein) or subcutaneously (under the skin) as a route of administration.

The global erythropoietin drug market report has been segmented on the basis of drug class, products, application and region. On the basis of region, the global erythropoietin (EPO) drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

To Get Sample Copy of Report visit @ https://marketresearch.biz/report/erythropoietin-epo-drugs-market/request-sample/

Currently, the market in North America dominates the global erythropoietin drug market in terms of revenue owing to patent expiration of biologics, various players have entered the market in this region. The market in Asia Pacific is projected to have fastest growth with highest CAGR, owing to increasing incidence of chronic disease.

Key players in the global erythropoietin drug market include, Johnson & Johnson LLC , Hospira Inc., F. Hoffmann-La Roche AG , Amgen Inc., Biocon Limited , Teva Pharmaceutical Industries Ltd., Ranbaxy Laboratories Ltd, Novartis International AG , Pfizer Inc., and LG Life Sciences Limited.

 

Editor Details

Last Updated: 15-Feb-2019